Review of NICE Technology Appraisal Guidance no.140; Infliximab for subacute manifestations of ulcerative colitis and no.163; Infliximab for the treatment of acute exacerbations of ulcerative colitis

The Institute was proposing that the decision to review TA163 should be deferred until the completion of the GETAID CYSIF and CONSTRUCT trials, and that the decision to review TA140 should be deferred until the completion of the single technology appraisal of adalimumab for the second-line treatment of moderate to severe ulcerative colitis (referred November 2010).

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

May 2011